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MAJOR PROFESSOR:  Dr. Derek Fisher 
Chlamydia trachomatis is an obligate intracellular bacterial pathogen that infects both 
humans and domestically important animals. Research in the field has, until more 
recently, been hindered by a lack of genetic tools. We have modified Sigma’s 
TargeTron™ Gene Knockout System, which utilizes a mobile group II intron for site-
specific insertion and gene inactivation, for use in C. trachomatis. As proof of principle, 
we used the system to inactivate incA, creating mutant strains DFCT3 and DFCT4 
(independent clones both carrying incA::GII[bla]). IncA is a chlamydial inclusion 
membrane protein involved in homotypic fusion of inclusions when cells are infected 
with more than one bacterium. Genotypic and phenotypic analyses were performed to 
ensure successful intron insertion into incA and loss of IncA function. Further 
characterization of the incA::GII(bla) mutant examined its pathogenicity relative to the 
wild type strain and indicated that the mutant was attenuated for growth in a mouse 
infection model, but not in a cell culture infection model. Complementation of the incA 
mutant confirmed that the phenotype differences between the wild type strain and the 
mutant were due to inactivation of incA.  As incA mutants arise spontaneously during 
human infections, future work will focus on the role of IncA in pathogenesis using the 
mutant strains derived from this study. 
 
 
ii 
 
ACKNOWLEDGMENTS 
 
I would first and foremost like to thank Dr. Derek Fisher for allowing me into his 
lab and onto this project. His guidance and seemingly infinite patience during all of my 
research as well as during the writing and revision of this thesis were invaluable.   
Additionally, I am grateful to Dr. Douglas Fix and Dr. Kelly Bender for taking time 
out of their schedules to serve on my thesis committee.  
There are many kind souls who shared vectors, antibodies, reagents, and ideas 
for my project to whom I am very thankful. I must individually acknowledge Dr. Laxmi 
Yeruva for generously carrying out the mouse infection experiments which provided 
important data for my project. 
I would be remiss to not thank my parents, William and Catherine Johnson, as 
well as the rest of my family, for their constant support. This includes my loyal canine 
companion, Olivia, for keeping me company and always being happy to see me. 
Finally, I thank all of my fellow graduate students and friends for laughing, 
thinking, and often commiserating with me.  
 
 
 
 
 
 
 
 
 
iii 
 
TABLE OF CONTENTS 
 
CHAPTER           PAGE 
ABSTRACT ...................................................................................................................... i 
ACKNOWLEDGMENTS ................................................................................................... ii 
LIST OF TABLES ............................................................................................................ iv 
LIST OF FIGURES .......................................................................................................... v 
CHAPTERS 
 CHAPTER 1 – Introduction ................................................................................... 1 
 CHAPTER 2 – Materials and Methods ............................................................... 11 
 CHAPTER 3 – Results ....................................................................................... 24 
 CHAPTER 4 – Discussion .................................................................................. 43 
REFERENCES .............................................................................................................. 52 
 
VITA .. ........................................................................................................................... 58 
 
 
 
 
 
 
 
 
 
iv 
 
LIST OF TABLES 
TABLE             PAGE 
Table 1.1 ......................................................................................................................... 2 
Table 1.2 ......................................................................................................................... 6 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
LIST OF FIGURES 
FIGURE           PAGE 
Figure 1.1 ........................................................................................................................ 4 
Figure 1.2 ........................................................................................................................ 5 
Figure 1.3 ........................................................................................................................ 9 
Figure 3.1 ...................................................................................................................... 26 
Figure 3.2 ...................................................................................................................... 28 
Figure 3.3 ...................................................................................................................... 30 
Figure 3.4 ...................................................................................................................... 31 
Figure 3.5 ...................................................................................................................... 32 
Figure 3.6 ...................................................................................................................... 34 
Figure 3.7 ...................................................................................................................... 36 
Figure 3.8 ...................................................................................................................... 38 
Figure 3.9 ...................................................................................................................... 40 
Figure 3.10 .................................................................................................................... 42
  
1 
 
CHAPTER 1  
INTRODUCTION 
 
Public health significance 
Chlamydia spp. are obligate, intracellular Gram negative bacterial pathogens that 
are responsible for a variety of human diseases and diseases that affect economically 
important domestic animals (Table 1.1) (Longbottom and Livingstone, 2006). Of 
particular importance to human health is Chlamydia trachomatis (causative agent of 
trachoma and sexually transmitted infections [STIs]), the leading cause of reportable 
bacterial infections worldwide. It is also responsible for the most common reportable 
bacterial sexually transmitted infection in the United States (Brunham and Rappuoli, 
2013). C. trachomatis may cause dangerous long-term complications if left untreated. In 
women, it increases the risk of pelvic inflammatory disease, infertility, and ectopic 
pregnancy (Chow et al., 1990; Healy et al., 1994; Paavonen and Lehtinen, 1996). In 
men, it can cause urethritis and lead to epididymitis and prostatitis, as well as 
decreased sperm viability (Mackern-Oberti et al., 2013). In addition to directly causing 
disease, co-infection with C. trachomatis and human papillomavirus (HPV) puts the 
affected female at an increased risk for cervical cancer (Samoff et al., 2005). Untreated 
C. trachomatis infection also elevates efficiency of HIV transmission (Schust et al., 
2012). These dangers are compounded by the frequently asymptomatic presentation of 
chlamydial sexually transmitted infections (Bébéar and de Barbeyrac, 2009). 
Chlamydia trachomatis is composed of several serological variants, known as 
serovars. Serovars A-C cause ocular infections, which are responsible for the most 
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common cause of preventable blindness worldwide (Burton and Mabey, 2009). 
Serovars D-K are sexually transmitted variants of C. trachomatis. Serovars L1-L3 cause 
the systemic sexually transmitted infection known as lymphogranuloma venereum 
(LGV) (Bébéar and de Barbeyrac, 2009).  
 
  
Table 1.1: Chlamydia species and diseases 
Organism Host Disease 
C. trachomatis Humans Trachoma, urethritis, pelvic inflammatory 
disease, ectopic pregnancy, lymphogranuloma 
venereum 
C. pneumoniae Humans Pneumonia, bronchitis 
C. muridarum Hamsters, mice Pneumonia 
C. psittaci Birds, humans Psittacosis, pneumonia 
C. abortus1 Ruminants, humans Fetal death, abortions 
C. suis2 Swine Conjunctivitis, pneumonia, enteritis 
C. pecorum Ruminants, 
marsupials 
Abortion, conjunctivitis, pneumonia, infertility 
C. felis1 Domestic cats Conjunctivitis, rhinitis 
C. caviae Guinea pigs Ocular inflammation 
 
1
 Vaccine commercially available 
2
 Some strains carry the tetR gene, tet(C) 
 
 
Bacterial growth and development  
 The Chlamydia undergo a unique biphasic developmental cycle in which the 
infectious, nonreplicative elementary body (EB) comes into contact with and attaches to 
a host cell (Figure 1.1A) (Abdelrahman and Belland, 2005). Upon contact, the EB is 
endocytosed where upon it resides within a host membrane-derived vesicle termed an 
inclusion (Figure 1.1B-C). For Chlamydia trachomatis, it is during the first few hours 
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within the inclusion that the EB will differentiate into the non-infectious, replicative 
reticulate body (RB) (Figure 1.1D). The RBs undergo rounds of replication via binary 
fission and the inclusion size increases to accommodate the growing number of 
bacteria. At about 18 hours post infection, the RBs begin asynchronously differentiating 
back into EBs (Figure 1.1E-H). Finally, at about 40 to 48 hours after infection is initiated, 
lysis of the inclusion and host cell allows the EBs to escape and for the infectious cycle 
to begin again in a new cell (Figure 1.1I). Length of the developmental cycle varies from 
about 40 to 72 hours depending upon the species. 
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Figure 1.1: Chlamydia developmental cycle. Modified and used with permission of 
Derek Fisher (Southern Illinois University). 
 
 
 Chlamydia spp. possess a type-three secretion system (T3SS) (Mueller et al., 
2014). The T3SS plays an important role in modifying the inclusion at the interface of 
the host cytosol and inclusion membrane, a significant point for interaction between the 
cell and the bacterium. A group of proteins termed inclusion membranes proteins, or 
Incs, are secreted by the T3SS early in infection and localize to the inclusion membrane 
(Mital et al., 2013). There are over 50 Incs predicted within the C. trachomatis genome. 
The Incs all have a characteristic bi-lobed hydrophobic domain of 40 amino acids or 
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more despite having a surprising lack of sequence similarity (Figure 1.2) (Ronzone and 
Paumet, 2013). Currently, the function of only a small portion of the Incs is known 
(Table 1.2) (Agaisse and Derré, 2014; Hackstadt et al., 1999; Lutter et al., 2013; Mital et 
al., 2013; Rzomp et al., 2006; Scidmore and Hackstadt, 2001). 
 
 
 
Figure 1.2: General Inc protein characteristics. The bi-lobed hydrophobic 
transmembrane (TM) region associates with the inclusion membrane while the C-
terminal region, whose function is Inc-specific, is exposed to the host cytosol and allows 
for interaction with host components. The IncA’s SNARE-like domains enable IncA to 
promote homotypic fusion of multiple inclusions, as well as block host endocytic 
SNARE-mediated membrane fusion (Ronzone and Paumet, 2013). 
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Table 1.2: Known functions of C. trachomatis Inc proteins 
C. trachomatis Inc proteins Known biological function 
IncA Homotypic fusion 
IncD CERT recruitment 
IncG Adapter protein 14-3-3β recruitment 
CT228 MYPT1 recruitment 
CT229 Rab4 recruitment 
 
 
 
 Typically, when more than one EB infects a single host cell, the multiple 
inclusions will fuse until only a single inclusion is visible within the cell. IncA, a T3SS 
substrate, has been implicated in the process of homotypic fusion. Experiments 
reported by Hackstadt et al. used microinjections with rabbit polyclonal antibodies 
against three different Inc proteins into C. trachomatis-infected HeLa cells (Hackstadt et 
al., 1999). The infected cells microinjected with the anti-IncA antibodies displayed 
multiple, non-fusing inclusions. In addition, clinical isolates have been found that lack a 
functional IncA protein (Suchland et al., 2000). Sequencing of these isolates revealed a 
variety of modifications to the incA gene ranging from frameshift mutations to base 
changes resulting in early termination during translation or deletions of up to 671 base 
pairs (bp) leading to the production of a truncated IncA (Rockey et al., 2002).  Mutants 
also have been identified with nucleotide changes resulting in a single amino acid 
difference within the characteristic hydrophobic domain that significantly modifies its 
hydrophobicity (Suchland et al., 2000). These isolates produce multiple, non-fusogenic 
inclusions in cells infected with more than one EB. 
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Genetic tools 
Despite the public health relevance of Chlamydia spp., research on these 
pathogens has been greatly hindered by two factors: 1) their obligate, intracellular 
lifestyle, which has made all previous attempts at developing a system of long-term 
axenic growth unsuccessful and 2) a paucity of genetic tools. However, researchers in 
the field have recently made great strides in addressing the need for useful genetic tools 
and limited growth under axenic conditions has now been achieved (Agaisse and Derré, 
2013; Kari et al., 2011; Mishra et al., 2012; Omsland et al., 2012; Wickstrum et al., 
2013). 
Within the past two years, Chlamydia cryptic plasmid-based expression platforms 
have been developed to allow for the expression of foreign and recombinant genes 
(Agaisse and Derré, 2013; Wickstrum et al., 2013). In addition, chemical mutagenesis 
using ethyl methanesulfonate (EMS) has been successfully employed for forward and 
reverse genetic approaches, and antisense RNA has been used for gene silencing (Kari 
et al., 2011; Mishra et al., 2012). However, the field still lacked a method of targeted 
chromosomal gene mutation.  
A mobile group II intron from Lactococcus lactis was previously modified for use 
in targeted gene disruption in prokaryotes (Lambowitz and Zimmerly, 2004). Bacterial 
genomes may contain both group I and group II introns. These are mobile catalytic RNA 
elements (Hausner et al., 2014; Lambowitz and Zimmerly, 2004). The ability of mobile 
group II introns to splice from an RNA sequence depends on the assistance of an 
intron-encoded protein (IEP) that is located within the intron sequence (Lambowitz and 
Zimmerly, 2004). Once excised, the intron RNA is able to splice directly into the target 
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location within a DNA sequence. Recognition of the DNA by the intron is based on 
sequence similarity between the DNA and specific sites within the intron, known as the 
intron and exon-binding sites (IBS and EBS) (Figure 1.3A) (Lambowitz and Zimmerly, 
2004). It is then reverse transcribed by the IEP, which in L. lactis is performed by the 
LtrA. Mobile group II introns share a conserved secondary structure essential for their 
catalytic activity despite minimal sequence similarity (Lambowitz and Zimmerly, 2004). 
Unlike group II introns, group I introns are self-splicing, eliminating the need for protein 
assistance to move from one location within the genome to another (Hausner et al., 
2014). Like group II introns, group I introns lack sequence similarity while retaining 
similar secondary structure. The insertion of group I or group II introns within an open 
reading frame may result in a truncated or total lack of protein if the intron does not 
splice out of the RNA (Saldanha et al., 1993). However, since both may be spliced out, 
protein production and function is typically restored under wild type conditions (Hausner 
et al., 2014; Lambowitz and Zimmerly, 2004). 
To utilize the specificity and efficiency of group II introns as a mutagenesis tool, 
modifications were made. Unlike the wild type L. lactis intron, the ltrA ORF is removed 
from within the intron and placed at the 3’ end of the exon (Figure 1.3B) (Perutka et al., 
2004). This ensures that, upon successful intron insertion and plasmid loss, the LtrA is 
lost and thus unable to splice the intron from the chromosome. In place of the ltrA ORF, 
an antibiotic resistance gene is inserted to allow for mutant selection. The plasmid has 
an origin of replication that, ideally, allows for propagation within E. coli, but not within 
the organism in which the target gene resides, ensuring loss of the plasmid upon intron 
mobilization and insertion. The plasmid also contains an antibiotic resistance cassette 
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located outside of the group II intron to allow for selection when propagating within E. 
coli (Perutka et al., 2004). This system is marketed as TargeTron™ by Sigma and relies 
upon a proprietary algorithm that allows for retargeting of the intron, via PCR and 
restriction digestion, based on the sequence of the gene to be inactivated.  
 
 
Figure 1.3: Wild type and modified Lactococcus lactis group II intron. (a) A simplified 
wild type L. lactis group II intron illustrates the location of the DNA recognition sites 
(IBS, EBS2, EBS1δ), as well as the location of the IEP (LtrA) within the intron. (b) A 
plasmid containing the modified group II intron in which the IEP has been moved and 
restriction sites added. Introns are retargeted by changing the sequence between the 
HindIII and BsrGI sites and “gene cargos” can be inserted at the MluI site. 
 
 
This project began with an attempt to further modify this system for use in 
Chlamydia and as proof of principle we used the system for the site-specific inactivation 
of incA in C. trachomatis L2 434/Bu. The resulting incA::GII(bla) mutant displayed a 
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non-fusogenic phenotype when one cell was infected with multiple EBs. Using a variety 
of methods, the stability of the insertion was subsequently demonstrated (at both the 
genotype and phenotype levels) over repeated passages in cell culture and in an animal 
infection model in the absence of selection.  More recent studies have begun to assess 
the pathogenicity of the mutant compared to that of the wild type parental strain using 
both cell culture and a mouse vaginal tract infection model. In addition, we have 
complemented the mutant to ensure that the growth phenotypes observed were due to 
the incA::GII(bla) mutation and not a second site mutation or polar effects. 
 
Aims 
 The goals of this project were to develop a method for targeted gene inactivation 
in Chlamydia and to demonstrate the utility of this approach for studying the biology of 
this important pathogen. 
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CHAPTER 2  
MATERIALS AND METHODS 
 
Culturing conditions 
 Mouse fibroblast L2 cells were routinely grown at 37oC with 5% CO2 in 
Dulbecco’s Modified Eagle Medium (DMEM) (HyClone, Thermo Scientific™) with 
GlutaMAX™ (Gibco ®, Life Technologies ™) supplemented with 10% fetal bovine 
serum (HyClone, Thermo Scientific™). PCR with degenerate primers to the 
Mycoplasma spp. 16s rRNA was used periodically to check the cells for mycoplasma 
contamination. All primers except for those listed in text are listed in Johnson and Fisher 
(Johnson and Fisher, 2013). 
 C. trachomatis was grown in L2 cells. Stocks were titered via the inclusion 
forming unit (IFU) assay and stored at -80oC in sucrose phosphate glycerine buffer 
(SPG, 0.19 mM KH2PO4, 0.36 mM K2HPO4, 0.245 mM L-glutamic acid, 10.9 mM 
sucrose). 
 E. coli strains were grown at 37oC on Luria-Bertani (LB) agar plates or in LB 
broth with antibiotics, as appropriate (chloramphenicol at 20 µg/mL, kanamycin at 50 
µg/mL, spectinomycin at 100 µg/mL, and/or ampicillin at 100 µg/mL [all from Fisher 
BioReagents]). 
 
IFU assay 
 Chlamydia samples were diluted in infection medium (DMEM, 10% FBS, 1× 
nonessential amino acids, and 0.2 µg/mL cycloheximide). 200 µl of the samples were 
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added per well of a black 96-well plate containing a confluent mouse L2 monolayer. To 
encourage simultaneous infection of cells, the plate was centrifuged at 545 × g for one 
hour and then incubated at 37oC for 24 hours (T0 = start of centrifugation). After the 24 
hour incubation, the infection medium was aspirated from the 96-well plate via suction 
and replaced with 200 µl of ice-cold methanol. The plate was incubated at room 
temperature for one hour or overnight at 4oC.  
 The methanol was removed via suction and one drop of PathfinderTM Chlamydia 
Culture System (Bio-Rad) was added to each infected well and incubated at room 
temperature in the dark for 30 minutes. The antibody was dumped from the plate and 
wells were rinsed with deionized water. The plate was blotted to remove excess liquid 
and one drop of mounting medium was added to each well (glycerol,10% phosphate 
buffered saline). Plates were either examined immediately or stored in the dark at 4oC 
and examined within 24 hours. 
 Plates were examined under a fluorescent microscope at 400× magnification 
under green fluorescence. Inclusions were counted in ten random fields per well and the 
titer determined via the following formula: 
(total IFU counted)   ×  233.96 fields per well  ×  dilution factor correction  =  IFU/mL 
  (total fields counted) 
 
TargeTron™ plasmid construction 
 The base TargeTron™ vector pACD4K-C (Sigma) was modified for use in 
Chlamydia by first removing the kanamycin resistance RAM cassette. The vector was 
digested with MluI (molecular biology reagents obtained from Thermo Scientific™ 
Fermentas unless noted otherwise), run on an agarose gel (using the GeneJET Gel 
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Extraction and Purification Kit, Thermo Scientific™), and purified. The digested, linear 
plasmid lacking the cassette was then recircularized via ligation with T4 DNA ligase. 
The ligation was transformed into E. coli DH5α and selected on LB plates containing 
chloramphenicol. Colonies were then patched onto both LB agar plates containing 
chloramphenicol and LB agar plates containing kanamycin. A clone found to be 
sensitive to kanamycin, but resistant to chloramphenicol was chosen and grown for 
plasmid isolation (using GeneJET Plasmid Miniprep Kit, Thermo Scientific™). RAM 
cassette loss was confirmed via PCR using primers GIIFtest and GIIRtest. This plasmid 
was designated pDFTT1. 
 pDFTT1 was further modified with the addition of a chlamydial promoter 
upstream of the GII 5’ exon. Genomic DNA from plaque-purified, clonal C. trachomatis 
434/Bu L2 strain ACE051 (from Anthony Maurelli, Uniformed Services University of the 
Health Sciences) was used to clone the 264 bp region upstream of the CTL0655 start 
codon. Primers CTL0655 proF and proR were used in the PCR reaction with Platinum 
Taq DNA Polymerase, High Fidelity. HindIII and XbaI were used to digest both the PCR 
product as well as pDFTT1. After agarose gel purification, the digested PCR fragment 
was ligated into the digested pDFTT1. The ligation product was then transformed into E. 
coli DH5α and plated onto LB agar plates containing chloramphenicol to select for 
transformants. PCR was used to screen for the presence of the insert and a positive 
clone was grown for plasmid preparation before further confirmation via sequencing. 
This plasmid was designated pDFTT2. 
 The bla cassette was then moved into pDFTT2 to confer ampicillin resistance to 
Chlamydia upon successful intron insertion. pGFP::SW2 (gift of Ian Clarke, University of 
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Southampton) was used as template in a PCR reaction with primers blaF and blaR and 
Phusion High-Fidelity PCR Master Mix to generate a fragment containing the bla gene. 
Both PCR fragment and pDFTT2 were digested with MluI, run on an agarose gel and 
purified. The bla-containing fragment was then moved into pDFTT2 via ligation. 
Transformants were selected on LB agar plates containing both ampicillin and 
chloramphenicol and screened via PCR using primers blaF and GIIRtest. pDFTT2(bla) 
was then sequenced for verification.  
 
Intron retargeting to incA 
 The C. trachomatis incA DNA sequence was submitted to the TargeTron™ 
Design Site and its proprietary algorithm used to determine the optimal site for intron 
insertion. Of the generated results, the insertion site was chosen based on the closest 
proximity to the 5’ start codon, as well as the lowest E-value (0.191).  
Three primers were generated based on the insertion site chosen (1608|1609-
IBS, 1608|1609-EBS 1d, 1608|1609-EBS2) and used along with primer EBS universal 
to generate a 350 bp PCR product. The product, as well as pDFTT2(bla), was digested 
with HindIII and BsrgGI. They were then run on an agarose gel, purified, and ligated to 
generate the retargeted pDFTT3. The ligation product was transformed into E. coli 
DH5α and clones isolated. Primer T7 pro was then used to sequence verify the clones. 
  
TargeTron™ transformation and selection 
 1×107 EBs were pipetted into a 1.5 mL microcentrifuge tube along with 3 µg 
pDFTT3 plasmid DNA. Molecular grade, sterile water was added to a volume of 160 µL 
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followed by 40 µL 5× CaCl2. The solution was mixed by pipetting up and down 10 times 
and then left for 30 minutes at room temperature. After the 30 minute incubation, 33.3 
µL of the transformation was added to 2 mL of ice-cold SPG for each well to be infected. 
This was then used to infect a confluent fibroblast L2 cell monolayer in a 6-well tissue 
culture plate via centrifugation for 1 hour at 545 × g. This infection is passage zero (P0). 
The mix was replaced with 2 mL DMEM/FBS and the plate incubated at 37oC with 5% 
CO2.  
 At 12 hours post infection (T0 = start of centrifugation), medium was replaced with 
2 mL DMEM/FBS supplemented with appropriate selection antibiotic (1 µg/mL ampicillin 
or 200 µg/mL spectinomycin).  
 Between 40-44 hours post infection, P0  was harvested. Sterile glass beads were 
added to the wells and the plate was rocked and swirled gently until no cells remained 
attached. The medium was transferred to a 50 mL conical tube and lysed via sonication 
with a 1/8-inch probe at 20% duty for 20 seconds. The sample was then centrifuged for 
20 minutes at 4oC at 10,000 × g. The supernatant was removed and discarded and the 
pellet suspended in 2.5 mL SPG by vortexing and pipetting.  
 The P0 harvest was then used to infect a confluent fibroblast L2 monolayer in a 
T75 flask. The flask was infected via rocking for two hours at 37oC with 5% CO2 (P1). 
The medium was then replaced with 20 mL of complete medium (DMEM, 10% FBS, 0.2 
µg/mL cyclohexamide, 1× nonessential amino acids) with 1 µg/mL ampicillin. The flask 
was incubated for 40-44 hours at 37oC with 5% CO2.  
 P1 was harvested by adding sterile glass beads to the flask and rocking until all 
cells appeared detached. The medium was transferred to a 50 mL conical tube and 
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lysed via sonication at 30% duty with a 1/8-inch probe for 20 seconds. The sample was 
centrifuged and suspended as for P0 harvest and used to infect P2 as for P1.  
 P2 was harvested as described for P1 harvest and used to infect P3 as described 
above, but with an increased concentration of ampicillin at 5 µg/mL. P3 was harvested 
as above and 1/3 of the harvest used to infect P4 as an additional round of enrichment, 
but with ampicillin again at 1 µg/mL. 
 P4 was harvested, titered via IFU assay, and used in plaque assays to obtain 
plaque-purified clones. Plaque assay infections and overlay feeds were done either in 
the presence or absence of 5 µg/mL ampicillin. Plaques were picked and expanded in 
the absence or presence of drug to match the conditions in which each was plaque 
purified. Expansion continued until each clone was used to infect eight T175 flasks 
which were then harvested, titered via IFU assay, and stocked at -80oC in SPG. 
 
Mutant genotype analysis 
 Genomic DNA was purified from clones DFCT3 and DFCT4 and ACE051 using 
the DNeasy Blood & Tissue Kit (Qiagen) and quantified via A260 nm absorbance using 
a Biotek Syngery HT microplate reader. PCR reactions were carried out using 2× PCR 
Master Mix (Thermo ScientificTM) and primers at 0.5 µM. Genomic DNA was used at 50 
ng and plasmid DNA was used at 10 ng per reaction. PCR products were run on an 
agarose gel and imaged via UV transillumination following ethidium bromide staining. 
 To sequence the insertion sites in the incA::GII(bla) clone, the ACE051, DFCT3, 
and DFCT4 incA regions were amplified. PCR with primers incAseqF and incAseqR 
was used to generate fragments containing incA that was flanked by StuI restriction 
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sites. The PCR products were run on an agarose gel and purified prior to StuI digestion. 
StuI was also used to digest pUC18. The digested PCR product was then ligated into 
the StuI-digested pUC18 and transformed into E. coli DH5α. Transformants were 
selected on LB agar plates containing ampicillin, which were also used for blue-white 
screening. Transformants were further verified by PCR and grown up for plasmid 
isolation. The isolated recombinant plasmids pUC18incA, pUC18incA::GII(bla)DFCT3, and 
pUC18incA::GII(bla)DFCT4 were sent for Sanger sequencing with primers GIIFtest, 
GIIRtest, blaF2, pUCF, and pUCR. 
 For Southern blot analysis, one of three enzymes (PstI, SphI, or SacI) was used 
to digest 2 µg of genomic DNA, which was then run on a 0.7% agarose gel. Ethidium 
bromide was used to stain the gels which were then viewed with a Spectrolinker ™ UV 
transilluminator (BioRad ChemiDoc MP System). DNA was then transferred from the gel 
to positively charged nylon membranes. DNA was crosslinked to the membrane using a 
UV crosslinker set to “optimal crosslink.” The membranes were probed for DNA 
fragments containing incA or bla by overnight treatment with DIG-labeled DNA probes 
at 42oC. High-stringency washes were carried out at 65oC before probe detection. 
Rosche’s alkaline phosphatase anti-DIG antibody-based DIG Nucleic Acid Detection Kit 
was used for detection of bound probes. Addition of the precipitating chromogenic 
substrate nitroblue tetrazolium chloride was used to visualize bound antibody. 
Deionized, distilled water was added to stop the reaction. Photographs of the blots were 
taken using a BioRad ChemiDoc MP System. 
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Western blotting of IncA and MOMP 
 Fibroblast L2 cells were grown in a 24-well culture plate until the monolayer 
reached ~90% confluence. Trypsin was added to three of the wells to detach cells. 
Trypan blue was added to the detached cells and used for counting. A multiplicity of 
infection (MOI) of ten was then used to infect wells with ACE051, DFCT3, or DFCT4, 
diluted in 1 ml complete infection medium, via centrifugation for one hour at 545 × g at 
room temperature. Cells were incubated for 24 hours post infection at 37oC with 5% 
CO2. A Leica DMIL inverted microscope was used to view cells. Photos were taken at 
400× with a Leica EC3 camera fitted to the microscope and utilizing imaging software 
Leica LASV4.1 for analysis.  
 For Western blotting, the medium was aspirated from the wells. The wells were 
washed with PBS, 250 µL of 1× Laemmli buffer (containing 358 mM β-mercaptoethanol) 
was added, and wells were scraped with a pipet tip to harvest the cells and bacteria. 
Samples were transferred to Eppendorf tubes and heated for five minutes at 95oC after 
sonication. Samples were run in triplicate on 12% SDS-PAGE gels to allow for 
Coomassie Brilliant Blue staining and anti-MOMP and anti-IncA Western blotting. One 
gel was stained with Coomassie Brilliant Blue and imaged to ensure equal loading of 
the samples. The remaining gels were processed for Western blotting. The samples 
were transferred from the SDS-PAGE gels to nitrocellulose membranes. The 
membranes were blocked with 5% milk Tris-buffered saline (MTBS). Rabbit anti-IncA 
(gift of Dr. Raphael Valdivia, Duke University) and mouse anti-MOMP antibodies (from 
Abcam, gift of Wiley Jenkens, Southern Illinois University) were diluted at 1:200 and 
1:1000, respectively, in MTBS and used to probe the gels overnight at 4oC. Membranes 
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were washed with TBS/Tween-20 (0.05% V/V). Secondary goat anti-rabbit-IgG-HRP-
conjugated antibody (Thermo ScientificTM Pierce, IncA blots) or anti-mouse-IgG-HRP-
conjugated antibodies (Millipore, MOMP blots) were diluted in MTBS at 1:5000 and 
used to probe the blots for one hour at room temperature. Blots were washed with 
TBS/Tween-20, then TBS, and finally treated with a chemiluminescent substrate 
(SuperSignal WestPico, Thermo ScientificTM Pierce). Processed blots were viewed and 
imaged with a BioRad ChemiDoc MP. Three independent infections were performed to 
assess IncA production. 
 
Light and immunofluorescence microscopy of mutants 
 Fibroblast L2 monolayers in a 24-well tissue culture dishes, with some wells 
containing acid-treated glass coverslips, were infected as for Western blotting. Cells 
were infected at MOIs of 0.01 and five, for time points at 24 and 48 hours, and an MOI 
of ten for the 24 hour time point only. Infected replicate wells without coverslips were 
viewed and imaged under phase contrast microscopy at 400× magnification. For 
immunofluorescence (IF) microscopy, cells were fixed and permeabilized as previously 
described. Chlamydia were immunodetected by treatment first with a primary mouse 
anti-MOMP antibody (Abcam), then by a Texas-Red-conjugated secondary donkey-anti-
mouse IgG antibody (Thermo ScientificTM) and finally stained with DAPI. Coverslips 
were then mounted onto glass slides using ProLong Gold anti-Fade (Life 
TechnologiesTM) and viewed using a Leica DM4000 fluorescent microscope. Coverslips 
were imaged with a QImaging QiClick Mono (QImaging) under oil immersion at 630× 
magnification. Images were processed with QImaging software (QImaging). 
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Complementation 
 A fragment which included wild type incA was cut from vector pUC19::incA via 
restriction digestion using KpnI and SalI. This fragment also contained a 47 bp 
upstream region in an attempt to include the incA promoter, the exact location of which 
is unknown. p2TK2-SW2 (gift of Isabelle Derré, Yale School of Medicine) was similarly 
digested with KpnI and SalI and both digested vector and incA fragment were run on a 
0.7% agarose gel and purified. The incA fragment was then ligated into digested 
p2TK2-SW2. The ligation product was then transformed into E. coli DH5α which was 
grown for plasmid isolation. p2TK2-SW2::incA was sent for Sanger sequencing using 
primers p2tkseqF and p2tkseqR (5’-GTTCTTTCCTGCGTTATCCC-3’; 5’-
TTGAAGCGCTCCGGATAGTG-3’, respectively). 
 To introduce the complementation and empty p2TK2-SW2 control vectors into 
DFCT9, the incA::GII(aadA) mutant strain, the same chemical transformation method 
was used as for the TargeTron™ transformation and selection. The recombinant strain 
phenotypes were examined via phase contrast microscopy under 400× magnification 
and images taken. The subsequent recombinant strains are DFCT6 (incA::GII[aadA] 
p2TK2-SW2) and DFCT7 (incA::GII[aadA] p2TK2-SW2::incA). 
 
Plaque Assays 
 60 mm plaque dishes with confluent L2 monolayers were infected with C. 
trachomatis via rocking for one hour at 37oC. 6 mL of overlay (0.5% SeaKem agarose, 
1× DMEM, 10% FBS, 1× NEAA, 0.2 µg/mL cycloheximide, and antibiotics as 
appropriate) was added after infection and allowed to solidify for 20 minutes at room 
  
21 
 
temperature before incubation at 37oC with 5% CO2. Plaques were fed with an 
additional 3 mL of overlay on days five and ten. On day 15, 1.5 mL neutral red was 
added to each dish and incubated for three hours at 37oC with 5% CO2. Neutral red was 
then aspirated, overlay removed and discarded, and dishes allowed to dry overnight. 
 
Measuring plaque size 
 Processed, dried plaque dishes were overturned and viewed on top of a light 
source. Plaques were measured at their longest point to the nearest tenth of a 
millimeter with a Peak Optics 7× loupe. Ten random plaques were measured per dish. 
Measurements were taken from duplicate plaque dishes within each trial over a series 
of three trials and then averaged.  
 
Plaque expansion 
 For plaque picking, 60mm plaque dishes were infected as described above, but 
were not processed with the addition of neutral red after the overlay removal on day 15. 
10 µL of SPG was added to a single plaque on the dish, gently scratched with a pipet 
tip, and pipetted up and down several times before freezing at -80oC until further 
expansion. 
 Each harvested plaque was used to infect an individual well in a confluent 24-
well plate via centrifugation for one hour at 545 × g before incubation at 37oC with 5% 
CO2. At 40 hours post infection, infected wells were harvested via addition of 500 µl 
Trition X-100 for five minutes and scraping with a pipet tip for ~20 seconds. Harvests 
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were centrifuged for five minutes at 13,000 × g at 4oC. Pellets were washed once with 1 
mL PBS and suspended in 500 µL SPG and stored at -80oC. 
 
Progeny production assay 
 Serial dilutions of wild type C. trachomatis and DFCT3 prepared in SPG were 
used to infect a 24-well plate with confluent L2 monolayers via centrifugation at 545 × g 
for one hour. 100 µL of each dilution was stored at -80oC for future titer of actual IFU 
input. Wells were visually observed and those with an MOI closest to 0.1 and three to 
five were chosen for harvest at 40 hours post infection. Harvests were performed via 
addition of 500 µl Triton X-100 for five minutes and scraping with a pipet tip for ~20 
seconds. Harvests were centrifuged for five minutes at 13,000 × g at 4oC. Pellets were 
washed once with 1 mL PBS and suspended in 500 µL SPG and stored at -80oC until 
titering via IFU assay. Three separate infections were performed, each trial in duplicate. 
Harvests were titered in triplicate.  
 
Mouse infections 
 BALB/c mice were pretreated with Depo-Provera to synchronize estrus and 
infected vaginally with 3×106 IFU of wild type C. trachomatis or DFCT3 (stocks prepared 
and provided by D. Fisher and the author). Vaginal swabs were taken every three days 
from day three through day 33 post infection. Swabs were used to infect McCoy cells for 
titering via IFU assay. Two trials were performed and each trial had five or six mice per 
experimental group. Infections and titering were performed by Dr. Laxmi Yeruva 
(University of Arkansas for Medical Sciences). 
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Mouse swab expansions 
 Swabs were used to infect wells in a 24-well plate with a confluent L2 monolayer. 
Wells were harvested at 40 hours post infection via addition of 500 µL Triton X-100 for 
five minutes and scraping with a pipet tip for ~20 seconds. Harvests were centrifuged 
for five minutes at 13,000 × g at 4oC. Pellets were washed once with 1 mL PBS and 
suspended in 1 mL SPG and stored at -80oC until further expansion. 
 Harvests were used to infect L2 cells in 24-well plates and harvested as before. If 
inclusions could be detected visually, harvests were used to infect L2 cells in 6-well 
plates. Once a sufficient number of inclusions were present, EBs were harvested by 
addition of glass beads and hand rocking to dislodge cells. SPG was added to 1× and 
harvests were stored at -80oC until further processing. 
 The inclusion phenotype was visually observed under phase contrast light 
microscopy at 400× magnification once an MOI of >1 was reached. Photos were taken 
with a Leica LASV4 camera. The genotypes were tested using PCR on DNA purified 
from harvests via Qiagen DNeasy Blood & Tissue Kit. 
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CHAPTER 3  
RESULTS 
 
Generating an incA::GII(bla) mutant 
 Mutants were obtained through chemical transformation, ampicillin selection, and 
isolated via plaque assay. Two plaque-purified mutants, DFCT3 and DFCT4, were 
chosen for additional analysis. 
 
Mutant confirmation 
 It was important to examine the genotype and phenotype of the incA::GII(bla) 
mutants after expansion and harvest. Intron stability in the clone expanded in the 
absence of selection would dictate whether or not mutants would be stable in the 
absence of selection during animal infection studies. Also, the desirability of this system 
lies in its ability to target with great specificity, making it essential to confirm its actual 
insertion location in the obtained clones. 
 Successful insertion of the intron was confirmed first through a series of PCR 
reactions (Johnson and Fisher, 2013). Primers were used to amplify a portion of incG, 
which is located near incA within the C. trachomatis genome, indicating that successful 
insertion of GII(bla) within incA had no effect on surrounding regions (Figure 3.1, 
Reaction 1). The cryptic plasmid was found to remain present in both the parental and 
mutant strains despite introduction of the TargeTron™ plasmid, pDFTT3 (Figure 3.1, 
Reaction 2). The size shift of incA due to intron insertion was apparent when using 
primers that sit within incA, flanking the insertion site (Figure 3.1, Reaction 3). Reactions 
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4 and 5 demonstrated the presence and orientation of the intron within incA in the two 
mutant strains using two different primer sets in which one primer was located within the 
intron and the other within the incA ORF (Figure 3.1). Primers specific for the intron 
yielded products for only the mutant strains and pDFTT3, indicating a lack of intron 
presence within the parental strain ACE051 (Figure 3.1, Reaction 6). Finally, primers 
specific for pDFTT3 only yielded product when plasmid DNA was used in the PCR 
reaction, indicating plasmid loss in the mutant strains after intron insertion (Figure 3.1, 
Reaction 7).  
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Figure 3.1: PCR verification of incA::GII(bla) mutants plaque-purified with or without 
ampicillin selection. Isolated genomic DNA from both mutant and parental strains, along 
with pDFTT3, were used in a series of PCR reactions to examine intron insertion, 
orientation, and presence or absence of cryptic and pDFTT3 plasmids. Maps of the wild 
type incA locus (a), incA::GII(bla) locus (c), C. trachomatis cryptic plasmid (b), and 
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pDFTT3 (d) show the location and expected product size of all PCR reactions 
performed. Figure taken from Johnson and Fisher (Johnson and Fisher, 2013).  
 
 
Southern blots were performed using three different restriction enzymes and 
probed for incA and the bla resistance cassette. The size shift of incA between parental 
strain ACE051 and mutant strains DFCT3 and DFCT4 was apparent after probing with 
an incA-specific DNA probe. The probe-bound fragment of both mutant strains ran at a 
higher molecular weight than did that of the parental strain, indicating the presence of 
the group II intron (Figure 3.2C-E). A probe specific for the ampicillin resistance 
cassette (bla) within the intron bound to DNA fragments only present in the mutant 
strains. In addition, the observation of a single bla fragment for each mutant indicates 
that only a single insertion event occurred (Figure 3.2C-E).  
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Figure 3.2: Southern blot verification of incA size and bla presence. (a) A map of the 
wild type incA locus with the location of probe binding, as well as bla probe binding 
upon intron insertion. (b) Expected product sizes after digestion. Genomic DNA from 
mutant and parental strains was digested with either SacI, PstI, or SphI and run on 
agarose gels, stained with ethidium bromide, and viewed with UV transillumination. 
DNA was then transferred to a nylon membrane, probed with DIG-labeled probes 
against incA or bla, and detected using anti-DIG antibodies conjugated to alkaline 
phosphatase. Probe association was visualized with chromogenic substrate. (c-e) DNA 
gels are shown alongside their respective Southern blots for all enzymes. Figure taken 
from Johnson and Fisher (Johnson and Fisher, 2013). 
 
 
Sanger sequencing was performed on pUC18 vectors carrying incA regions 
amplified from the parental and mutant strains. The inserts in mutant strains DFCT3 and 
DFCT4 had identical sequences and were also found to have inserted at the predicted 
location within the chromosome (position 108 within the incA open reading frame). 
Sequences were published by Johnson and Fisher (Johnson and Fisher, 2013). 
 
 
Phenotypical analysis 
Western blots confirmed the loss of IncA production. Protein samples from 
infected cells or mock-infected cells were run on three 12% SDS-PAGE gels. One was 
stained with Coomassie Brilliant Blue and imaged to confirm equal loading of samples 
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(Figure 3.3A). The other two gels were processed for Western blotting: one for anti-
MOMP and the other for anti-IncA antibody treatment. Treatment with anti-MOMP 
assured the presence of Chlamydia in all loaded samples (Figure 3.3B). Finally, anti-
IncA antibody failed to detect any IncA protein in the samples obtained from cells 
infected with the incA::GII(bla) mutants, but did react with the ACE051 parental strain 
sample (Figure 3.3C). These results indicate that the GII intron insertion into incA on the 
chromosome resulted in disrupted production of IncA. Consistent with the absence of 
detectable IncA by Western blot, the non-fusogenic phenotype also was observed via 
light microscopy as well as immunofluorescence (Figure 3.4 and 3.5). 
 
 
 
Figure 3.3: Western blot analysis of IncA function. Fibroblast L2 cells were infected with 
mutant strains, parental strain, or mock infected at an MOI of ~10. At 24 hours post 
infection, cells were lysed with Laemmli buffer and run on three 12% SDS-PAGE gels. 
One gel was stained with Coomassie Brilliant Blue (a). The other two gels were 
transferred to nitrocellulose membranes for anti-MOMP (b) or anti-IncA blotting (c). The 
predicted masses of MOMP and IncA are 42.5 kDa and 30.3 kDa, respectively. Figure 
taken from Johnson and Fisher (Johnson and Fisher, 2013). 
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Figure 3.4: IncA-null phenotype observed via phase contrast light microscopy. L2 cells 
were infected with parental strain ACE051 or mutant strains DFCT3 and DFCT4 at 
MOIs of ~10 (a-c), ~5 (j), or ~0.1 (d-i). Images were taken under 400× magnification 
with phase contrast microscopy at 24 (a-f) or 48 hours (g-j) post infection. Arrows 
indicate inclusions. Figure taken from Johnson and Fisher (Johnson and Fisher, 2013). 
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Figure 3.5: Immunofluorescence analysis of the incA::GII(bla) mutant phenotype. 
ACE051, DFCT3, and DFCT4 were used to infect cells at an MOI of ~10. Cells were 
fixed at 24 hours post infection for treatment with mouse anti-MOMP (visualized with 
Texas Red-conjugated goat anti-mouse secondary antibody) for Chlamydia detection 
(b, e, h), followed by DAPI staining (a, d, g). For image overlays in panels c, f, and i, 
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DAPI was false colored blue and anti-MOMP was false colored red. Blue arrows 
indicate cell nuclei while red arrows indicate chlamydial inclusions. Images were taken 
at 630× magnification under oil immersion using a fluorescent microscope. Infection and 
immunofluorescence was carried out three times. Figure taken from Johnson and Fisher 
(Johnson and Fisher, 2013). 
 
 
In vitro and in vivo growth properties 
Plaque size 
 After examining the genotype and phenotype of the incA::GII(bla) mutant, the 
question arose of whether this strain would be attenuated due to lack of IncA 
expression. The ability to plaque was tested by measuring the size of individual plaques 
of the mutant strain grown under the same conditions, and measured alongside the 
parental strain. Plaques were measured at the longest point, from end to end. The data 
are representative of three separate trials in which dishes were infected in duplicate. 
Data were analyzed with a Student’s t-test for significance (p-value  of 0.05). The 
mutant strain produced plaques that were not significantly different in size than plaques 
produced by the parental strain (Figure 3.6A). The incA:GII(bla) non-fusogenic 
phenotype was apparent when plaque dishes were viewed at 400× magnification 
(Figure 3.6B). 
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Figure 3.6: Comparison of mutant and wild type strain plaque sizes. DFCT3 and 
ACE051 were used to infect cells in 60 mm plaque dishes. Dishes were incubated for 
two weeks and fed on days five and ten post infection. On day 14, dishes were 
processed and allowed to dry after overlay removal. Processed, dry plaque dishes were 
overturned and viewed on a light source and 10 random plaques were measured per 
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dish. Infections were performed in duplicate and the experiment was repeated three 
times. (a) Average plaque size. (b) Phase contrast micrograph of mutant plaque 
phenotype at 400× magnification. White arrows indicate cells containing multiple non-
fusogenic inclusions. Error bars represent standard error, n=3. 
 
 
Progeny production 
In addition to plaquing ability, the incA::GII(bla) mutant was assessed for its 
ability to produce infectious progeny at numbers similar to that of the wild type strain. 
Progeny production was assessed in vitro by infecting confluent fibroblast L2 
monolayers with either wild type or mutant strain at MOIs of ~0.1 and ~3-5. Infections 
were harvested at 40 hours post infection and titered. The harvested EBs were titered 
alongside a portion of the dilution used to infect that well to allow for direct comparison. 
The production was expressed in terms of infectious progeny harvested per EB used for 
infection.  
When data were analyzed using a Student’s t-test (p-value of 0.05), the ratio of 
infectious progeny produced by the incA::GII(bla) mutant was not found to be 
significantly different than the parental strain (Figure 3.7). Both plaque size and progeny 
production results suggest that the mutant strain was not attenuated in an in vitro 
infection model compared to the wild type strain. 
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Figure 3.7: Wild type and mutant in vitro progeny production. Cells were infected in a 
24-well plate with wild type and mutant strains at MOIs of ~0.1 and three to five. Wells 
were harvested at 40 hours post infection via Triton X-100 and scraping. Harvests and 
input samples were both titered via the IFU assay. Infections were performed in 
duplicate and the experiment repeated three times. Error bars represent standard error, 
n=3.  
 
 
 
Animal infection model 
 To determine whether the incA::GII(bla) strain behaved similarly in an animal 
infection model as it did in vitro, BALB/c mice were infected with either the wild type 
strain or mutant strain. Vaginal swabs were taken every three days from day three post 
infection through day 33. The number of infectious progeny obtained with the swabs 
was determined via IFU assay. 
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The yield in terms of IFU/mL differs from trial one to trial two, but the general 
trend is very similar (Figure 3.8). In both cases, the swabs taken from mice infected with 
the wild type strain of C. trachomatis contained a higher number of infectious progeny 
throughout the first half of the infection than did those taken from mice infected with the 
incA::GII(bla) strain. These data suggest that the mutant strain is attenuated for growth 
in the mouse infection model, but not in a mouse fibroblast L2 cell culture infection 
model. 
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Figure 3.8: Animal model infection. BALB/c mice were infected vaginally with wild type 
and mutant strains. Swabs were taken every three days from day three to day 33 post 
infection and titered via the IFU assay. Results from experiment one (a) and experiment 
two (b) with wild type in red and incA::GII(bla) mutant in blue. Five to six mice were 
infected per experimental group. Error bars indicate standard deviation. 
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Intron stability  
 The in vivo infection data suggest that the wild type C. trachomatis produces 
more infectious progeny through day 15. After day 15, the number of progeny produced 
by the incA::GII(bla) mutant appears much more similar to the wild type strain.  
 To test for the presence of the intron and maintenance of an IncA-null phenotype 
throughout in vivo infection, swabs taken from the mice were used to infect confluent 
monolayers of fibroblast L2 cells and expanded until several inclusions were visible per 
field under 400× phase contrast microscopy. At that point, the wells were harvested and 
DNA isolated. The isolated chlamydial DNA was used in PCR reactions using primers 
flanking the GII(bla) insertion site within incA. Figure 3.9 shows the results from swabs 
taken from both wild type and mutant C. trachomatis infections. The wild type swabs 
from days nine and twelve produced a fragment size consistent with wild type incA. The 
PCR product from the mutant swabs from days six and nine ran at a size indicating the 
presence of the GII(bla) insert (Figure 3.9A). Swabs taken from incA::GII(bla)-infected 
mice on days 24 and 27 were tested as those were time points in which the progeny 
production of the mutant approached that of the wild type strain. Again, the PCR 
fragments generated in this reaction ran higher than the wild type incA, indicating that 
the GII(bla) insert had not been lost (Figure 3.9B). 
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Figure 3.9: Genotype analysis to confirm the incA::GII(bla) mutation in mouse swab 
expansions. Swabs taken from infected mice were expanded in fibroblast L2 cells and 
harvested. Once detectable levels of inclusions were present, the harvests were 
processed for use in PCR reactions to test for GII insert presence at time points early in 
infection (a) and late in infection (b). Experimental sample labels indicate the day (D) on 
which the swab was taken, whether the mouse was from the group inoculated with the 
wild type (WT) or mutant (M) strain, and the mouse number. 
 
 
Complementation 
 It was important to demonstrate that all of the observed incA:GII(bla) 
characteristics were due solely to the absence of IncA. Manipulation of any gene has 
the potential for unseen effects outside of the target gene. As a result, expression of the 
wild type incA gene from a plasmid resulting in restoration of the wild type phenotype 
can ensure that the GII(bla) insertion had no unexpected results, such as polar effects, 
on the expression of other genes.  
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 Upon the fourth passage of the incA::GII(aadA) mutant strain carrying either 
p2TK2-SW2 or p2TK2-SW2::incA in tissue culture, the phenotype difference became 
apparent as every cell was infected with an MOI ~3. The strain carrying empty p2TK2-
SW2 vector retained the non-fusogenic inclusion phenotype characteristic of the IncA-
null mutant C. trachomatis (Figure 3.10A). The strain carrying the complementation 
vector p2TK2-SW2::incA, however, appeared to display a phenotype consistent with 
that of wild type C. trachomatis (Figure 3.10B). In this complemented strain, every cell 
appeared to contain only a single inclusion despite having an MOI >1. 
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Figure 3.10: Complementation of the incA::GII(aadA) mutant. Chemical transformation 
was used to move p2TK2-SW2 or p2TK2-SW2::incA into DFCT9. Transformants 
carrying p2TK2-SW2 (a) or p2TK2-SW2::incA (b) were selected with ampicillin and 
passaged in fibroblast L2 cells until the phenotype could be visualized. Images were 
taken under phase contrast microscopy at 400× magnification. 
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CHAPTER 4  
DISCUSSION 
 Despite being treatable with antibiotics such as azithromycin and doxycycline, 
Chlamydia trachomatis infections continue to pose a threat to public health. Infections 
left untreated due to asymptomatic presentation or lack of access to antibiotics may 
cause a wealth of complications including blinding trachoma for ocular infections, and 
ectopic pregnancy, pelvic inflammatory disease, and infertility for sexually transmitted 
infections (Burton and Mabey, 2009; Chow et al., 1990; Healy et al., 1994; Paavonen 
and Lehtinen, 1996). Additionally, Chlamydia may enter into a persistent state in which 
the bacteria do not replicate, but may begin growing again when the inhibitor is 
removed, such as when antibiotics are no longer present (Hogan et al., 2004). While 
antibiotic resistance has not yet been seen in C. trachomatis, some strains of 
Chlamydia suis carry a gene that confers resistance to tetracycline (Suchland et al., 
2009). Further, it has been shown that the tet(C) gene from C. suis is capable of being 
horizontally transferred to other species of Chlamydia (C. trachomatis and C. 
muridarum) in co-infection experiments, indicating that acquisition of antibiotic 
resistance genes is feasible (Suchland et al., 2009).  
Recently, research has been done suggesting that the gastrointestinal tract may 
in fact be a reservoir for Chlamydia, resulting in long-term colonization (Yeruva et al., 
2013b). Animals are known to become infected in the GI tract with Chlamydia via the 
fecal-oral route. Interestingly, azithromycin treatment at levels sufficient for clearing 
genital tract infections was found to be ineffective for clearing GI tract infections in mice 
(Yeruva et al., 2013a). Presence of Chlamydia in the GI tract has also been confirmed 
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in humans (Rank and Yeruva, 2014). Since azithromycin has been shown to be 
ineffective at clearing GI tract infections, individuals may still be at risk for reinfection, as 
well as infection of sexual partners, even after successful antibiotic treatment for genital 
infections. 
Due to the problems associated with detection and antibiotic treatment of 
infections, prevention of infection would be desirable. While vaccines currently exist for 
C. abortus and C. felis for use in animals, vaccine development and basic research in 
general has been hindered due to a lack of tools for genetic manipulation and lack of 
axenic growth conditions, until more recently (Longbottom and Livingstone, 2006; 
Omsland et al., 2012). Chemical mutagenesis has been employed to introduce random 
chromosomal mutations, antisense RNA has been used for gene silencing, and cryptic 
plasmid-based expression platforms have been developed for gene expression 
(Agaisse and Derré, 2013; Kari et al., 2011; Mishra et al., 2012). Still, the field lacked a 
method of creating targeted chromosomal mutations. To address this deficiency, we 
modified the TargeTron™ system for use in Chlamydia to allow for targeted gene 
inactivation. 
Use of the TargeTron™ system in Chlamydia enables researchers to target and 
inactivate genes without the cost and time associated with TILLING-based mutagenesis 
approaches. In addition, the use of multiple selection markers would enable the targeted 
inactivation of multiple genes. There is also potential for the study of expression when 
combined with the recent development of a tetracycline-inducible on/off system 
(Wickstrum et al., 2013). The stability of the intron makes it ideal for use in animal 
model infections. However, it would still be less than ideal for use in developing a live-
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attenuated vaccine. In such cases, a complete deletion achieved by a method such as 
allelic exchange would be desirable. Despite the stability of the intron observed in our 
study, a true deletion eliminates any possibility of restoration of the complete wild type 
gene transcript.  
As proof of principle, incA was targeted for inactivation because naturally-
occurring IncA mutant clinical isolates have been found (Suchland et al., 2000). This 
indicated that insertionally inactivating the incA gene would not be lethal for the 
bacterium. Furthermore, C. trachomatis isolates that lack functional IncA possess a 
readily observable non-fusogenic inclusion phenotype. Microinjection experiments with 
anti-IncA supported IncA’s role in fusion of multiple inclusions in a host cell upon 
infection with multiple EBs (Hackstadt et al., 1999). Our creation and examination of an 
isogenic incA::GII(bla) mutant further supports the role of IncA in chlamydial inclusion 
fusion (Johnson and Fisher, 2013). 
The creation of incA::GII(bla) mutants was performed in several independent 
trials by different members of the lab using independently-prepared EB stocks, buffers, 
as well as pDFTT3 plasmid DNA preparations. The mutants were first examined visually 
after several passages under ampicillin selection for the presence of the IncA-null 
phenotype. The characteristic non-fusing inclusions were apparent under light 
microscopy as well as immunofluorescence microscopy (Figure 3.4 and 3.5). Genotypic 
analysis of genomic DNA isolated from mutants DFCT3 and DFCT4 confirmed the 
single insertion of the GII(bla) within incA via Southern blot (Figure 3.2). PCR and 
sequencing determined that the insertion event occurred at the predicted location and in 
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the correct orientation and that pDFTT3 was lost (Figure 3.1). Finally, Western blot 
analysis confirmed the loss of IncA production (Figure 3.3). 
Reintroduction of the incA gene via transformation of p2TK2-SW2::incA into the 
mutant strain resulted in the production of functional IncA (detected via Western blot, 
data not shown, D. Fisher) as well as restoration of the wild type fusogenic inclusion 
phenotype (Figure 3.10). Complementation was essential in ensuring that the mutation 
within incA did not result in any secondary mutations or polar effects in other genes. 
The latter point is of greater concern for genes that lie within an operon, which incA 
does not. Complementation studies have been extremely limited in C. trachomatis and 
this is only the third instance of complementation (Chen et al., 2014; Snavely et al., 
2014). 
After genotypic and phenotypic analysis of the incA::GII(bla) mutant, further 
characterization of the mutant was performed to examine its pathogenicity in vivo and in 
vitro compared to the wild type strain. Plaque dish infection assays indicated that the 
mutant strain produced plaques that were not significantly different in size than those of 
the wild type strain (Figure 3.6). However, the plaques were only measured in one 
dimension. Future studies should measure plaque area as the mutant plaques did show 
a larger-size trend and area might be a more accurate way to compare plaque size. At 
the very least, growth was not attenuated in the mutant strain in the plaque assays. 
Production of infectious progeny was examined in vivo and in vitro. Infections of 
mouse fibroblast L2 cells demonstrated that the incA::GII(bla) mutant progeny 
production trend was greater than that of the wild type strain, but like the plaque results, 
not different in a statistically significant manner (Figure 3.7). Intriguingly, swab titers 
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from mouse infection experiments were higher for the wild type strain than for the 
mutant during the first few weeks of infection (Figure 3.8). Unlike the cell culture trends, 
the differences between the wild type strain and mutant strain titers in the animal model 
were statistically significant using repeated measures two-way ANOVA with Bonferroni 
correction (p-value of 0.05) (L. Yeruva, unpublished). Thus, the incA::GII(bla) mutant 
appeared to be attenuated for growth in vivo, but not in vitro.    
C. trachomatis clinical isolates that possess a non-fusogenic phenotype occur at 
a frequency of approximately 1.5%, higher than frequencies indicative of random 
mutations (Suchland et al., 2000). These isolates persist in clinical infection, but always 
at a similar frequency while the wild type continues to predominate. This implies that the 
wild type strain has the advantage under most conditions, but not all, or the mutant 
phenotype would be absent or present at considerably lower frequency. The cell culture 
data from our study would support an advantage for the IncA-null mutant over the wild 
type strain, but fails to take the innate and adaptive immune responses into account. 
The animal model may more accurately reflect what occurs in human infections in terms 
of the immune response as it appears to significantly affect the success of the mutant 
strain. It is possible that early response by members of the innate immune system, such 
as polymorphonuclear leukocytes (PMNs), to greater production of infection progeny by 
the mutant strain results in decreased titers compared to the wild type strain (Rank et 
al., 2011). Then, at later time points in which the adaptive immune response, including 
CD8+ T-cells, respond to IncA, the wild type strain titers decrease more dramatically 
relative to the IncA-null strain (Wizel et al., 2002).  
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Initially, we hypothesized that the IncA-null strain would demonstrate attenuated 
growth in a cell culture infection model. We hypothesized that the presence of multiple 
inclusions within a single host cell would result in more competition for the scavenging 
of host nutrients when compared to a single, larger inclusion within a host cell. 
However, our data did not support this hypothesis and indicated that the exact opposite 
may be true. Instead of increased competition, the presence of multiple inclusions may 
provide a greater total surface area per bacterium across which to move nutrients from 
the host. This greater surface area to volume ratio would theoretically allow for more 
efficient nutrient uptake and could explain the increased progeny production by the 
mutant. This could be tested by calculating the actual surface area of the non-fusogenic 
inclusions within a single host cell compared to that of a single wild type inclusion. 
Additionally, the increased progeny numbers could be due to greater RB 
production per inclusion prior to conversion to EBs. Hoare et al. have hypothesized that 
the triggering factor for RB to EB differentiation is decreased contact between the RB 
and the inclusion membrane as inclusion size increases (Hoare et al., 2008). Thus, after 
an EB has differentiated into an RB, it may undergo replication only as long as a certain 
amount of contact is maintained with the inclusion membrane. As bacterial load 
increases within the inclusion, it grows to accommodate them and decreases physical 
contact with each RB. At a certain threshold of contact, the RBs then begin 
differentiating back into EBs. In the context of our findings where the non-fusogenic 
incA::GII(bla) strain may produce more progeny than its fusogenic parental strain, this 
hypothesis may provide a possible explanation. The presence of multiple, smaller 
inclusions within the same host cell would allow more contact per RB with the inclusion 
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membrane. This would enable a greater number of replication events to occur before 
the threshold is met to signal RB to EB differentiation. This hypothesis could be tested 
by using the original model to determine how many RBs could be supported within the 
multiple non-fusogenic inclusions verses the single inclusion before they being to 
differentiate into EBs. This could then be tested experimentally by infecting cells with 
mutant and wild type strains at different MOIs to compare actual progeny production 
versus the calculated output based on number of inclusions.  
In contrast to the cell culture infection model, the animal model infections showed 
that the mutant strain was attenuated for growth compared to the wild type strain during 
the first two weeks of infection. However, the titers of wild type and mutant strains 
leveled off and appeared similar during the second half of the infection, raising concerns 
about the stability of the intron in vivo. It was possible that the incA::GII(bla) mutant 
strain lost the GII(bla) insert at some point during the infection, allowing restoration of 
the incA gene and production of functional IncA. This would explain why the titers 
appeared similar for only the last half of infection. We were able to disprove this by 
genotypic and phenotypic analysis of the vaginal swabs taken from the infected mice. 
Swabs taken from the incA::GII(bla) strain-infected mice at time points late in the 
infection, points at which mutant and wild type strain titers became similar, still 
displayed the non-fusogenic mutant phenotype upon expansion in cell culture. Further, 
the genomic DNA isolated from those same swabs was found to have retained the 
intron. Thus, we concluded that similar titers of mutant and wild type strains seen late in 
infection were not a result of mutant strain reversion to wild type as a result of intron 
loss. 
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Another possibility is that growth of the wild type strain decreased during the 
second half of infection, resulting in a clearance rate equal to the mutant strain. Sera 
from C. trachomatis-infected patients have been found to contain antibodies against 
IncA (Bannantine et al., 1998). Also, the IncA homolog found in C. pneumoniae is a 
known CD8+ T-cell antigen (Wizel et al., 2002). If the adaptive immune system (which 
typically takes approximately ten days to develop) does in fact respond to IncA during 
infection, this could explain why the wild type titers from the animal infection model were 
reduced to levels matching those of the mutant IncA-null strain. To test this hypothesis, 
sera from mice infected with the wild type and mutant strains could be assessed for 
anti-IncA reactivity.  
The in vitro data indicating that the mutant grows as well or better than the wild 
type strain were not mirrored in the results observed during the first half of the animal 
model. One possible explanation for the disadvantage of the incA::GII(bla) mutant strain 
during the first two weeks of infection in vivo could be an increased rate of progeny 
production during early infection. In a cell culture infection model, responses by the 
innate and adaptive immune system are absent. Thus, increased numbers may fail to 
elicit a response similar to what would occur in vivo. For early infection time points, the 
innate immune system would be responsible for bacterial clearance. For chlamydial 
infections in particular, PMNs have been found to be important for early clearance 
(Rank et al., 2011). If this innate immune system was triggered more strongly by the 
presence of increased progeny numbers by the mutant during the first 48 hours of 
infection, the production of fewer progeny by the wild type strain might allow that strain 
to persist more efficiently than the mutant strain. Examination of tissue sections during 
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the first 24-72 hours of infection to measure PMN influx should be performed in future 
studies. 
Collectively, this research project has resulted in the development of a tool for 
creating targeted chromosomal mutations in Chlamydia and has demonstrated the 
applicability of this method for delineating aspects of chlamydial pathogenesis through 
study of the incA::GII null mutant. 
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